Retinitis Pigmentosa 11: Clinical Trials

3 trials for Retinitis Pigmentosa 11, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 1 completed. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Active not recruiting 1, Completed 1
Phase 21Active not recruiting 1

Follow Retinitis Pigmentosa 11: new trials by email Literature Review of Retinitis Pigmentosa 11 trials Research Report on Retinitis Pigmentosa 11

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration
Phase 1 / Phase 2Active not recruitingPYC Therapeutics172025-06-012026-05-29
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
VP-001 - Retinitis Pigmentosa 11, Retinal Degeneration
Phase 1CompletedPYC Therapeutics62024-06-132026-05-29
Natural History Study of Retinitis Pigmentosa Type 11
Clinical examinations - Retinitis Pigmentosa 11, Retinitis Pigmentosa
Active not recruitingOslo University Hospital302021-02-012025-03-21

Narrower conditions

Retinal Degeneration (2)  ·  Retinal Diseases (2)  ·  Retinal Dystrophies (2)  ·  Eye Diseases (1)  ·  Eye Diseases, Hereditary (1)  ·  Retinitis (1)  ·  Retinitis Pigmentosa (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Eye Diseases (2)  ·  Eye Diseases, Hereditary (2)  ·  Genetic Diseases, Inborn (2)  ·  Retinal Degeneration (1)  ·  Retinal Diseases (1)  ·  Retinal Dystrophies (1)

Interventions

Physical Examination (1)

Sponsors

PYC Therapeutics (2)  ·  Oslo University Hospital (1)

Countries

United States (2)  ·  Norway (1)

Top investigators

Josephine P Holtan, MD, PHD (1)